Triton Systems is a Global Business Venture company that successfully launches innovative products and solutions in emerging markets worldwide. We invest in new technologies through in-house incubation and external partnerships – creating thriving businesses from novel ideas.

Business Ventures

Triton commercializes innovative technologies and transforms them into successful businesses. From cancer treatment to flame retardant plastic to waste water management, we impact global markets creating $3.8 Billion in shareholder value.

Ventures Include:

Aduro Biotech

Aduro Biotech (Aduro), a Triton launched company formed in 2010, stays at the forefront of discovery, development and commercialization of immunotherapies, alone or in combination; that make transformative advances in the treatment of challenging diseases.

FRX Polymers, Inc.

FRX Polymers, Inc., a (formed by Triton in 2007) manufactures Nofia® polyphosphonates - fire resistant plastics. Nofia products are fully transparent, high flowing and, due to their high phosphorus content, are inherently flame retardant. 

Emefcy

Emefcy specializes in developing energy-efficient wastewater treatment solutions. The company’s innovative Membrane Aerated Biofilm Reactor (MABR) technology is installed at sites around the world.

Sensera

Sensera is an integrated, fast turnaround client-specific designer and manufacturer of specialized high performance microsensors and micro-fabricated components for the Healthcare, Industrial, Defense and Aerospace markets.

Emerging Technologies

Key to our process is to research, identify and incubate emerging technologies that are in line with our strategic market focus. Through our in-house incubation operations or through outside partnerships and adopted technologies, we provide market driven solutions that effect the world around us. Emerging technologies include:

Featured Incubated Products

Traceptor™ Preconcentrator

A Plug and Play ‘Sensitivity Amplifier’ that enables chemical sensors for threat and contraband detection.

MEMS Sensors & Manufacturing

Sensera designs, engineers and manufactures MEMS-based sensors and other devices for industrial, medical and defense applications.

FRA Composites
(Fiber Reinforced Aluminum)

Triton FRA Composites is a fiber reinforced aluminum composite that offers light weight and high strength alternatives to heavy steel for bearing applications.

Latest News

Triton Receives Tibbetts Award at White House Ceremony

January 10, 2017, Chelmsford, MA:Triton Systems, Inc. (Triton) announced today that it has received a Tibbetts Award from the US Small Business Administration during a White House ceremony in Washington D.C. This prestigious national award award is given to companies who have successfully leveraged Small Business Innovation Research (SBIR) grants and have generated great value to the firm and to the nation.

Read More

Sensera Announces it has Acquired Nanotron Technologies

Will Position Sensera as Leading Sensor Network Company in Rapidly Growing IoT Space

September 12, 2017, Chelmsford, MA: Sensera Limited (ASX: SE1) (Sensera or the Company), an integrated designer and manufacturer of specialized high performance microsensors, is pleased to announce it has acquired Nanotron Technologies GmbH (Nanotron), a leading provider of location awareness systems.

 

Read More

 

 

Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (Pembrolizumab) for the Treatment of Mesothelioma

Second Phase 2 Clinical Collaboration between the Two Companies to Evaluate CRS-207/Pembrolizumab Combination

BERKELEY, Calif., May 17, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today the expansion of its clinical collaboration with Merck (known as MSD outside the United States and Canada) to include an additional Phase 2 clinical trial. The companies will investigate the combination of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with malignant pleural mesothelioma (MPM) whose disease progressed following prior treatment.

Read More

 

Emefcy and RWL Water Merge to Create Fluence, a Full-Service Distributed Water Solutions Corporation

NEW YORK – July 17, 2017 – Emefcy Group Limited (ASX: EMC) (“Emefcy”) and RWL Water LLC have completed their definitive merger agreement effective July 14, 2017 to form Fluence Corporation Limited (“Fluence”) (ASX: FLC), bringing together breakthrough technologies and proven delivery platforms to optimize treatment solutions for the water cycle for the 21st century.

Read More